Target e scelte terapeutiche nella gestione dell’ipertensione arteriosa nei pazienti diabetici. Le linee guida ESC 2024
Il Diabete · 07.05.2026 · 38 (1)
DOI: 10.30682/ildia2601b ↗Kurz gefasst
Fachartikel in der Zeitschrift Il Diabete, online erschienen am 07.05.2026. Verfasst von Marcello Rattazzi und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Patients with diabetes have a markedly increased cardiovascular risk, making blood pressure control a cornerstone of prevention. The 2024 ESC Guidelines emphasize early treatment even in patients with elevated blood pressure, guided by global cardiovascular risk assessment and tools such as SCORE2-Diabetes. Evidence from major trials, including ACCORD-BP, SPRINT, STEP, ESPRIT and BPROAD, supports lower blood pressure targets (120–129/70–79 mmHg) when treatment is well tolerated. Combination therapy, preferably as fixed-dose combinations, improves efficacy and adherence. In resistant hypertension spironolactone remains the preferred add-on therapy, while SGLT2 inhibitors may provide additional benefit in the presence of chronic kidney disease or heart failure. In selected cases, renal denervation is emerging as a complementary therapeutic option when optimal medical therapy fails.
Zitieren
APA
Rattazzi, M., Tonon, L., & Buso, R. (2026). Target e scelte terapeutiche nella gestione dell’ipertensione arteriosa nei pazienti diabetici. Le linee guida ESC 2024. Il Diabete, 38(1). https://doi.org/10.30682/ildia2601b
Vancouver
Rattazzi M, Tonon L, Buso R. Target e scelte terapeutiche nella gestione dell’ipertensione arteriosa nei pazienti diabetici. Le linee guida ESC 2024. Il Diabete. 2026;38(1). doi:10.30682/ildia2601b
BibTeX
@article{Rattazzi2026,
author = {Rattazzi, Marcello and Tonon, Luca and Buso, Roberta},
title = {Target e scelte terapeutiche nella gestione dell’ipertensione arteriosa nei pazienti diabetici. Le linee guida ESC 2024},
journal = {Il Diabete},
year = {2026},
volume = {38},
number = {1},
doi = {10.30682/ildia2601b}
}
EUVIMED